• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺素E1在脂质乳剂中的释放速率与滞留性

Rate of release and retentivity of prostaglandin E1 in lipid emulsion.

作者信息

Yamaguchi T, Fukushima Y, Itai S, Hayashi H

机构信息

Department of Pharmaceutics, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.

出版信息

Biochim Biophys Acta. 1995 Jun 6;1256(3):381-6. doi: 10.1016/0005-2760(95)00085-q.

DOI:10.1016/0005-2760(95)00085-q
PMID:7786903
Abstract

The rates of release of prostaglandin E1 (PGE1) from lipid particles into aqueous solution were obtained by the dialysis method, for parenteral lipid emulsion (Lipo-PGE1) diluted 10-times with buffered solutions of various pH. The findings, which were the rates of release of PGE1, were used to calculate the amount of PGE1 distributed in lipid particles when Lipo-PGE1, diluted 100-times with various pH levels of the buffered solution, was administered by intravenous drip infusion. More than 90% of PGE1 was retained in the lipid particles and intravenously infused when transfusion fluid pH was less than 5.5 and 2 ml of Lipo-PGE1 and 198 ml of transfusion fluid had been mixed and were administered over 2 h. Results from simulation showed that half of the PGE1 was retained in lipid particles and was infused, if Lipo-PGE1 was diluted 100-times with pH 8 transfusion fluid. Though PGE1 was sparingly soluble in an aqueous solution, these findings demonstrated that a significant amount of PGE1 was retained in lipid particles. Thus, this dosage form is expected to be highly effective for a drug delivery of PGE1 in clinical treatment.

摘要

通过透析法,获取了前列腺素E1(PGE1)从脂质颗粒释放到水溶液中的速率,该实验使用了用不同pH缓冲溶液稀释10倍的肠胃外脂质乳剂(前列地尔脂质微球)。当用不同pH值的缓冲溶液将前列地尔脂质微球稀释100倍后通过静脉滴注给药时,用这些作为PGE1释放速率的实验结果,来计算分布在脂质颗粒中的PGE1的量。当输液pH值小于5.5,将2ml前列地尔脂质微球与198ml输液混合并在2小时内给药时,超过90%的PGE1保留在脂质颗粒中并通过静脉输注。模拟结果显示,如果用pH值为8的输液将前列地尔脂质微球稀释100倍,一半的PGE1会保留在脂质颗粒中并被输注。尽管PGE1在水溶液中的溶解度很小,但这些结果表明大量的PGE1保留在脂质颗粒中。因此,这种剂型有望在临床治疗中对PGE1的药物递送具有高效性。

相似文献

1
Rate of release and retentivity of prostaglandin E1 in lipid emulsion.前列腺素E1在脂质乳剂中的释放速率与滞留性
Biochim Biophys Acta. 1995 Jun 6;1256(3):381-6. doi: 10.1016/0005-2760(95)00085-q.
2
Pharmaceutical quality evaluation of lipid emulsions containing PGE1: alteration in the number of large particles in infusion solutions.
Int J Pharm. 2009 Aug 13;378(1-2):167-76. doi: 10.1016/j.ijpharm.2009.05.026. Epub 2009 May 22.
3
Progress in the prostaglandin E1-therapy of the intermittent claudication by means of bolus injections of LIPO-prostaglandin E1 (LIPO-PGE1).通过大剂量注射脂微球载前列腺素E1(LIPO-PGE1)治疗间歇性跛行的前列腺素E1疗法进展。
Eur J Clin Pharmacol. 1996;51(3-4):235-9. doi: 10.1007/s002280050190.
4
[Clinical effects of lipo-prostaglandin E1 in patients with delayed cerebral vasospasm].脂微球载前列腺素E1治疗迟发性脑血管痉挛的临床疗效
No Shinkei Geka. 1987 Jun;15(6):635-40.
5
Development, Optimization, and Characterization of PEGylated Nanoemulsion of Prostaglandin E1 for Long Circulation.用于长循环的前列腺素E1聚乙二醇化纳米乳剂的研发、优化及表征
AAPS PharmSciTech. 2016 Apr;17(2):409-17. doi: 10.1208/s12249-015-0366-1. Epub 2015 Jul 21.
6
[Lipo prostaglandin E1 administration in the acute stage following subarachnoid hemorrhage].
No Shinkei Geka. 1988;16(5 Suppl):509-15.
7
Alteration of therapeutic efficacy of lipid microspheres incorporating prostaglandin E1 by mixing with aqueous solution.
J Pharm Sci. 2007 Apr;96(4):935-43. doi: 10.1002/jps.20790.
8
Determination of the pH-dependent phase distribution of prostaglandin E1 in a lipid emulsion by ultrafiltration.
Pharm Res. 1988 Aug;5(8):482-7. doi: 10.1023/a:1015961122982.
9
Association and release of prostaglandin E1 from liposomes.前列腺素E1从脂质体中的缔合与释放。
Biochim Biophys Acta. 1997 Jul 5;1327(1):97-106. doi: 10.1016/s0005-2736(97)00049-7.
10
Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers.脂微球载体前列腺素E1,一种新型的前列腺素E1脂质包裹制剂:糖尿病性神经病变和腿部溃疡患者的安慰剂对照及前列腺素E1对照多中心试验
Prostaglandins. 1993 Nov;46(5):453-68. doi: 10.1016/0090-6980(93)90081-h.

引用本文的文献

1
Elimination of the biphasic pharmacodynamics of 15d-PGJ2 by controlling its release from a nanoemulsion.通过控制15d - PGJ2从纳米乳剂中的释放来消除其双相药效学。
Int J Nanomedicine. 2016 Jun 8;11:2685-94. doi: 10.2147/IJN.S106297. eCollection 2016.
2
Surface composition regulates clearance from plasma and triolein lipolysis of lipid emulsions.表面成分调节脂质乳剂从血浆中的清除及三油酸甘油酯的脂解作用。
Lipids. 1998 Aug;33(8):773-9. doi: 10.1007/s11745-998-0269-8.
3
In vivo ESR studies on pharmacokinetics and metabolism of parenteral lipid emulsion in living mice.
Pharm Res. 1996 May;13(5):729-33. doi: 10.1023/a:1016047532687.